Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390104 | 0.90 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL3168629 | 0.86 | GPR119 (0.51) | GPR119CYP2C9PIK3CD | |
| SCHEMBL27734761 | 0.86 | GPR119 (0.49) | GPR119CYP2C9PIK3CD | |
| SCHEMBL1071546 | 0.83 | GPR119 (0.56) | GPR119CYP2C9PIK3CDNTRK1 | |
| SCHEMBL27734782 | 0.81 | GPR119 (0.48) | GPR119CYP2C9PIK3CD | |
| SCHEMBL27755351 | 0.80 | GPR119 (0.51) | GPR119CYP2C9PIK3CD | |
| SCHEMBL1068483 | 0.79 | GPR119 (0.52) | GPR119CYP2C9PIK3CDNTRK1 | |
| SCHEMBL27734866 | 0.77 | GPR119 (0.50) | GPR119CYP2C9PIK3CDNTRK1 | |
| SCHEMBL389602 | 0.76 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL27734759 | 0.76 | GPR119 (0.56) | GPR119CYP2C9PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101420941-A | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies | ARENA PHARM INC (US) | 2009-04-29 | — | — | CN | disclosed |
| CN-101332303-A | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level | ARENA PHARM INC (US) | 2008-12-31 | — | — | CN | disclosed |